Kaplan–Meier survival analyses with log-rank tests indicated that no difference had been demonstrated in NSCLC patients with different expression level of RUNX3 (P=0.2338, Figure 5(a)) or EZH2 (P=0.8489, Figure 5(c)), while NSCLC patients with higher expression of H3K27me3 demonstrated better prognosis in survival (P=0.0085, Figure 5(b)). The gene discussed is EZH2; the disease is non-small cell lung carcinoma.